Home  »  Stock   »  4D Molecular Therapeutics Inc. (FDMT): Lucky inves...

4D Molecular Therapeutics Inc. (FDMT): Lucky investors are lined up for success

For the readers interested in the stock health of 4D Molecular Therapeutics Inc. (FDMT). It is currently valued at $17.51. When the transactions were called off in the previous session, Stock hit the highs of $17.60, after setting-off with the price of $15.66. Company’s stock value dipped to $15.18 during the trading on the day. When the trading was stopped its value was $15.45.Recently in News on February 22, 2023, 4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™. All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints at relatively low dose of 1E13 vg/kg. You can read further details here

4D Molecular Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $26.49 on 12/13/22, with the lowest value was $5.32 for the same time period, recorded on 06/16/22.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


4D Molecular Therapeutics Inc. (FDMT) full year performance was 14.59%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, 4D Molecular Therapeutics Inc. shares are logging -33.90% during the 52-week period from high price, and 229.14% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $5.32 and $26.49.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 609905 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the 4D Molecular Therapeutics Inc. (FDMT) recorded performance in the market was -21.16%, having the revenues showcasing -28.68% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 586.59M, as it employees total of 140 workers.

4D Molecular Therapeutics Inc. (FDMT) in the eye of market guru’s

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 18.53, with a change in the price was noted +9.76. In a similar fashion, 4D Molecular Therapeutics Inc. posted a movement of +125.94% for the period of last 100 days, recording 452,415 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for FDMT is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

4D Molecular Therapeutics Inc. (FDMT): Stocks Technical analysis and Trends

Raw Stochastic average of 4D Molecular Therapeutics Inc. in the period of last 50 days is set at 31.07%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 39.89%. In the last 20 days, the company’s Stochastic %K was 17.23% and its Stochastic %D was recorded 15.17%.

If we look into the earlier routines of 4D Molecular Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -21.16%. Additionally, trading for the stock in the period of the last six months notably improved by 93.27%, alongside a boost of 14.59% for the period of the last 12 months. The shares increased approximately by 1.98% in the 7-day charts and went up by -13.79% in the period of the last 30 days. Common stock shares were lifted by -28.68% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts